Finance

Beta
Lists
JANX:NASDAQ
Janux Therapeutics Inc
$15.78
-2.23%
(-0.36) 1D
$15.78
0.00% (0.00)
After hours
Closed: Jul 14, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JANX...
Open
$16.10
High
$16.35
Low
$15.76
Mkt. cap
962.33M
Avg. vol.
1.24M
Volume
847.32K
52-wk high
$35.25
52-wk low
$12.12
EPS
-$1.84
Beta
2.52
Shares outstanding
60.98M
No. of employees
108
Open
$16.10
High
$16.35
Low
$15.76
Mkt. cap
962.33M
Avg. vol.
1.24M
Volume
847.32K
52-wk high
$35.25
52-wk low
$12.12
EPS
-$1.84
Beta
2.52
Shares outstanding
60.98M
No. of employees
108
News stories
From sources across the web
About Janux Therapeutics Inc
CEO-
Employees108
Founded2017
Headquarters-
SectorBiotechnology
Websitejanuxrx.com
Analyst ratings
Based on 14 analysts giving stock ratings to JANX in the past 3 months
Strong buy
Buy
12
Hold
1
Sell
1
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for JANX in the last 3 months.
Highest
Current $15.78
$60.00 (+280.23%)
Average
$31.00 (+96.45%)
Lowest
$14.00 (-11.28%)
Analyst
Recommendation
Action
Price target
Projected
Date
Supawat Thongthip
Truist Financial
Buy
Initiated
$26.00
+64.8%
06/25/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$22.00
+39.4%
05/11/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$45.00
+185.2%
05/11/2026
Oliver McCammon
LifeSci Capital
Buy
Reiterated
$60.00
+280.2%
05/09/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$36.00
+128.1%
05/08/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$58.00
+267.6%
05/07/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$26.00
+64.8%
05/08/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$21.00
+33.1%
05/08/2026
Boris Peaker
JonesTrading
Buy
Maintained
$28.00
+77.4%
05/08/2026
Etzer Darout
Barclays
Sell
Reiterated
$14.00
-11.3%
05/08/2026
Matt Phipps
William Blair
Buy
Reiterated
$14.00
-11.3%
05/08/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
05/08/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$36.00
+128.1%
05/08/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$38.00
+140.8%
04/28/2026
David Dai
UBS
Hold
Downgraded
$15.00
-4.9%
04/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
$50.00
+216.9%
04/06/2026
Karina Rabayeva
Truist Financial
Buy
Reiterated
$80.00
+407%
03/03/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$100.00
+533.7%
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
10.00M
-
3.73M
Cost of goods sold
29.18M
34.63M
31.55M
26.81M
Cost of revenue
29.18M
34.63M
31.55M
26.81M
Research and development expenses
5.49M
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.45M
10.62M
10.85M
11.13M
Operating expense
15.94M
10.62M
10.85M
11.13M
Total operating expenses
45.12M
45.25M
42.40M
37.95M
Operating income
-45.12M
-35.25M
-42.40M
-34.21M
Other non operating income
-
-
-
-
EBT including unusual items
-33.86M
-24.31M
-31.95M
-24.36M
EBT excluding unusual items
-33.86M
-24.31M
-31.95M
-24.36M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-33.86M
-24.31M
-31.95M
-24.36M
Net profit margin
-
-243.13%
-
-652.59%
Earnings per share
-0.55
-0.39
-0.51
-0.39
Interest and investment income
11.26M
10.94M
10.46M
9.85M
Interest expense
-
-
-
-
Net interest expenses
11.26M
10.94M
10.46M
9.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-44.58M
-34.75M
-41.93M
-33.74M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer